Switzerland The first company to bring a treatment for metabolic dysfunction-associated steatohepatitis (MASH) to market, Madrigal Pharmaceuticals is redefining how the world tackles fatty liver disease. From its new European base in Zug, the firm is building an entirely new therapeutic category while spearheading one of the most ambitious global launches…
Switzerland Neil Archer, Executive Vice President International at Madrigal, discusses the company’s pioneering role in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis), a progressive liver disease with no prior approved therapies. He shares insights on Madrigal’s breakthrough first-in-class treatment, the challenges of launching an entirely new therapeutic category, and the bold international expansion…
USA While the year’s tally of green lights from the FDA’s Center for Drug Evaluation and Research (CDER) is lower than the previous year’s, 2024 saw several long-awaited therapies reach the finish line. Oncology remained the single largest focus area among last year’s endorsed therapies and as opposed to 2023 when…
Global After a 12-year stint at Sanofi, Bill Sibold is leaving Big Pharma to join the Pennsylvania-based biotech Madrigal Pharmaceuticals as CEO. Sibold, no stranger to ground-breaking launches, having brought the blockbuster Dupixent to market, will be coming onboard just ahead of what looks to be a pivotal moment for Madrigal.…
See our Cookie Privacy Policy Here
